Krumbholz M, Metzler M (2021)
Publication Type: Book chapter / Article in edited volumes
Publication year: 2021
Publisher: Humana Press Inc.
Edited Volumes: Ewing Sarcoma
Series: Methods in Molecular Biology
City/Town: New York
Book Volume: 2226
Pages Range: 39-45
DOI: 10.1007/978-1-0716-1020-6_4
Liquid biopsies enable noninvasive therapy monitoring in patients with solid tumors. Specific serum markers such as proteins, hormones, or enzymes released from tumor cells or in response to tumor growth can be used for quantification of the tumor burden. However, only a fraction of pediatric tumors has none of these serum markers, but tumor-specific genetic alterations represent reliable alternatives. Here we describe a method for using genomic fusion sequences as liquid biopsy markers in Ewing sarcoma patients.
APA:
Krumbholz, M., & Metzler, M. (2021). Liquid Biopsies in Ewing Sarcoma. In Florencia Cidre-Aranaz, Thomas G. P. Grünewald (Eds.), Ewing Sarcoma. (pp. 39-45). New York: Humana Press Inc..
MLA:
Krumbholz, Manuela, and Markus Metzler. "Liquid Biopsies in Ewing Sarcoma." Ewing Sarcoma. Ed. Florencia Cidre-Aranaz, Thomas G. P. Grünewald, New York: Humana Press Inc., 2021. 39-45.
BibTeX: Download